PDCD1 and precursor B-cell acute lymphoblastic leukemia: Overall, our study demonstrates that certain cases of human B-ALL express PD-1, and that targeting this pathway with checkpoint inhibitors can activate NK cell activity, thereby presenting a potential therapeutic opportunity.